BLINCYTO 35/38.5 mcg
- Name: BLINCYTO
- Generic Name: Blinatumomab
- Strength: 35 mcg | 38.5 Single-Dose Vial
- Manufactured : Amgen Inc
Blincyto contains Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. Blincyto uses are:
- B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1%.
- Relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).
Note: – Blincyto is an FDA approved drug.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.